NOVAVAX INC Loss Contingency, Damages Sought, Value
NOVAVAX INC (NVAX) had Loss Contingency, Damages Sought, Value of $1.50 million as of 2021-08-23, per its 10-K filed 2023-02-28.
Discontinued › Notes › Commitment and Contingencies › Loss Contingency › Loss Contingency, Information about Litigation Matters
us-gaap:LossContingencyDamagesSoughtValue · last filed 2023-02-28
- 2021-08-23: Loss Contingency, Damages Sought, Value $1.50M.
| Period end | Loss Contingency, Damages Sought, Value |
|---|---|
| 2021-08-23 | $1.50M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |